Adopting early noninvasive cardiac testing is a cost-effective strategy for avoiding a future heart attack or death in patients with suspected acute coronary syndrome, according to a study published May 24 in Academic Emergency Medicine.
Researchers conducted a retrospective analysis of 89,387 Kaiser Permanente Southern California patients to examine care costs and quality-adjusted life-years associated with early noninvasive cardiac testing.
Here are five notes from the study:
- Of the 89,387 patients included in the study, 19% received early noninvasive cardiac testing.
- Total care costs were higher by $2,357 for patients who received early noninvasive cardiac testing compared to patients who did not. The higher costs were mainly attributed to the patient’s initial emergency department visit.
- In a one-year follow-up, patients who received early noninvasive cardiac testing had a 3.7% lower composite risk of nonfatal heart attack or death.
- Researchers determined that early noninvasive cardiac testing was cost-effective at $5,268 per quality-adjusted life-years.
- “Due to the significant clinical benefits, early noninvasive cardiac testing [is] cost-effective in the low- and intermediate-risk patients [and] a dominant strategy in high-risk patients saving cost and quality-adjusted-life-years,” the study authors wrote.
Read the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.